GeneHealth - Your precision medicine

Aldh7a1-related Disorder

Disease Details

Family Health Simplified

Buy Membership

Description: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy, is an inherited metabolic condition characterized by seizures that typically do not respond to common anticonvulsant medications but improve with vitamin B6 (pyridoxine) supplementation.
Type: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy, is generally transmitted in an autosomal recessive manner.
Signs And Symptoms: Aldehyde dehydrogenase 7 family, member A1 (ALDH7A1)-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is a rare genetic condition.

**Signs and Symptoms:**
1. **Seizures**: Frequent and severe seizures that often begin in the neonatal period or early infancy.
2. **Response to Pyridoxine**: Seizures typically respond well to high doses of pyridoxine (vitamin B6).
3. **Developmental Delay**: Motor and cognitive developmental delays are common.
4. **Other Neurological Symptoms**: These can include spasticity, hypotonia, and dystonia.
5. **Intellectual Disability**: Varying degrees of intellectual disability are often observed.
6. **Behavioral Issues**: Hyperactivity, aggressiveness, and autism spectrum disorder characteristics may be present.

Other symptoms can include irritability, poor feeding, and abnormal movements. Regular monitoring and appropriate vitamin B6 supplementation are critical for managing this disorder.
Prognosis: Aldh7a1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), typically has a favorable prognosis if diagnosed and treated early with vitamin B6 (pyridoxine) supplementation. Early and adequate treatment can control seizures and prevent intellectual disability. Without timely treatment, children may experience recurrent seizures, leading to potential developmental delays and cognitive impairment. Regular monitoring and lifelong adherence to vitamin B6 supplementation are usually recommended to manage the condition effectively.
Onset: ALDH7A1-related disorder, also known as Pyridoxine-Dependent Epilepsy (PDE), typically has an onset in the neonatal period. In most cases, seizures begin in the first days to weeks of life.
Prevalence: The prevalence of ALDH7A1-related disorder, also known as Pyridoxine-Dependent Epilepsy (PDE), is not precisely known but is estimated to be rare, occurring in approximately 1 in 400,000 to 1 in 700,000 live births.
Epidemiology: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is an ultra-rare genetic condition. The precise prevalence is not well-established due to its rarity and potential underdiagnosis, but it is estimated to affect approximately 1 in 100,000 to 1 in 700,000 live births globally. This autosomal recessive disorder is characterized by seizures that begin in infancy or early childhood and are responsive to pyridoxine (vitamin B6) treatment.
Intractability: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy, is not entirely intractable. While the seizures associated with this condition can be severe and resistant to standard anti-seizure medications, they typically respond well to treatment with pyridoxine (vitamin B6) and sometimes additional supplementation with a lysine-restricted diet. Early diagnosis and treatment are crucial to manage symptoms effectively.
Disease Severity: Aldh7a1-related disorder, also known as Pyridoxine-Dependent Epilepsy (PDE), typically presents with severe early-onset seizures that are resistant to conventional anticonvulsant medications. These seizures usually begin in the neonatal period or early infancy. The condition can also be associated with developmental delays and intellectual disability if not properly managed. Prompt diagnosis and treatment with high doses of pyridoxine (vitamin B6) can significantly improve outcomes and reduce the severity of the disorder.
Pathophysiology: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is caused by mutations in the ALDH7A1 gene, which encodes the enzyme antiquitin. This enzyme is vital for lysine metabolism. Pathophysiologically, the disorder results in an accumulation of toxic metabolites that interfere with neurotransmitter synthesis and function. This leads to a state of excitotoxicity, primarily affecting the central nervous system, and causing intractable seizures that are typically responsive to pyridoxine (vitamin B6) supplementation.
Carrier Status: For ALDH7A1-related disorder (also known as pyridoxine-dependent epilepsy), carrier status typically refers to an individual who has one normal copy and one mutated copy of the ALDH7A1 gene. Carriers usually do not exhibit symptoms of the disorder but can pass the mutated gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit two mutated copies of the gene and be affected by the disorder.
Mechanism: ALDH7A1-related disorder, also known as Pyridoxine-Dependent Epilepsy (PDE), is caused by mutations in the ALDH7A1 gene, which encodes the enzyme aldehyde dehydrogenase 7 family member A1.

**Mechanism:**
1. **Enzyme Deficiency:** The ALDH7A1 enzyme deficiency leads to an accumulation of its substrates, specifically α-aminoadipic semialdehyde (α-AASA) and related compounds.
2. **Disrupted Lysine Metabolism:** These compounds are intermediates in the lysine degradation pathway. Their buildup disrupts normal neurotransmitter balance and activity in the brain.
3. **GABA and Glutamate Imbalance:** Accumulation of these toxic metabolites affects neurotransmitter levels such as gamma-aminobutyric acid (GABA) and glutamate, leading to neuronal hyperexcitability.

**Molecular Mechanisms:**
1. **Alpha-AASA Accumulation:** The faulty enzyme cannot convert α-AASA to α-aminoadipic acid efficiently, leading to elevated levels of α-AASA and its cyclic derivative, Δ1-piperideine-6-carboxylate (P6C).
2. **P6C and Pyridoxal 5'-Phosphate (PLP) Interaction:** P6C reacts with pyridoxal 5'-phosphate (PLP), the active form of vitamin B6. This results in PLP depletion, which is crucial for the function of many enzymes, including those involved in neurotransmitter synthesis.
3. **Neurotransmitter Synthesis Impaired:** Reduced PLP levels negatively impact the synthesis of neurotransmitters, particularly GABA and serotonin, exacerbating seizure susceptibility and other neurological symptoms.

Management usually involves lifelong supplementation with pyridoxine (vitamin B6) to bypass the block and replenish neurotransmitter synthesis, helping control seizures and other symptoms associated with the disorder.
Treatment: For ALDH7A1-related disorder, there is no specific treatment that can cure the condition. However, management typically involves dietary adjustments and supplementation to control the symptoms. A pyridoxine (vitamin B6)-rich diet and pharmacological doses of pyridoxine are commonly used. Additionally, lysine-restricted diets and arginine supplementation may be considered to manage seizures and other related symptoms. Regular monitoring and consultations with a metabolic specialist are essential for ongoing management.
Compassionate Use Treatment: Aldh7a1-related disorder, primarily known as pyridoxine-dependent epilepsy (PDE), is a rare genetic condition usually treated with pyridoxine (vitamin B6). For compassionate use or experimental treatments, here are some considerations:

1. **Antisense Oligonucleotide Therapy**: Researchers are exploring this type of therapy to target specific genetic mutations in aldh7a1-related disorders.

2. **Gene Therapy**: Although still experimental, gene therapy aims to correct the underlying genetic mutation, potentially providing a long-term solution.

3. **Combination of Pyridoxine and Folinic Acid**: While pyridoxine is the standard treatment, adding folinic acid may be beneficial for some patients, though evidence is still emerging.

4. **Ketogenic Diet**: Sometimes used off-label, a ketogenic diet can help manage seizures in patients who do not fully respond to pyridoxine.

5. **Other B-Vitamins**: In some cases, additional B-vitamin supplements might be used experimentally to manage symptoms.

Consultation with a medical professional specializing in genetic or metabolic disorders is essential for exploring these treatment options.
Lifestyle Recommendations: For individuals with ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE):

1. **Medication Compliance**: Strict adherence to prescribed pyridoxine (vitamin B6) supplementation is crucial to manage seizures effectively.

2. **Dietary Adjustments**: A low-lysine diet may be recommended, as it can help reduce the buildup of toxic compounds that contribute to the disorder.

3. **Regular Monitoring**: Frequent follow-ups with healthcare providers to monitor growth, development, and seizure control are important.

4. **Avoid Triggers**: Identify and avoid known seizure triggers, which may vary among individuals.

5. **Education and Support**: Engage with educational and support resources, including special education services if developmental delays are present.

6. **Family Involvement**: Ensure family members are educated about the disorder, seizure management, and emergency protocols.

7. **Healthy Lifestyle**: Promote a balanced diet, regular physical activity (as tolerated), and sufficient sleep to overall well-being.

8. **Stress Management**: Implement stress-reducing activities as stress can potentially contribute to seizure activity.

For detailed and personalized advice, consulting a healthcare provider is essential.
Medication: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is treated primarily with high doses of pyridoxine (vitamin B6). This condition can be challenging to manage, and supplemental anticonvulsant medications may also be necessary. Close medical supervision is required to monitor treatment efficacy and adjust dosages as needed.
Repurposable Drugs: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is a rare genetic condition characterized by seizures that do not respond well to standard anticonvulsant medications but improve with pyridoxine (vitamin B6) administration. Research into repurposable drugs for this disorder is ongoing, with the primary treatment remaining pyridoxine supplementation. In some cases, adjunctive treatment with lysine-restricted diets or lysine-reducing agents like arginine has been explored to reduce the accumulation of toxic intermediates. However, more studies are needed to validate the efficacy of these approaches.
Metabolites: ALDH7A1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is a rare genetic condition caused by mutations in the ALDH7A1 gene. One marker of this disorder is the accumulation of specific metabolites in the body.

Metabolites associated with ALDH7A1-related disorder include:

1. **α-Aminoadipic Semialdehyde (α-AASA)**: Elevated levels of this metabolite in biological fluids are a characteristic finding in individuals with ALDH7A1-related disorder.
2. **Piperideine-6-carboxylate (P6C)**: This metabolite also accumulates and can be measured in urine, plasma or cerebrospinal fluid.
3. **Pipecolic Acid**: Increased levels of plasma pipecolic acid can also be observed.

These metabolites are typically assessed through specialized biochemical tests to aid in the diagnosis of ALDH7A1-related disorder.
Nutraceuticals: There are no specific nutraceutical interventions recognized for ALDH7A1-related disorders, which are typically managed with dietary modifications to control seizures and metabolic abnormalities. ALDH7A1-related disorders are often treated with pyridoxine (vitamin B6) and a lysine-restricted diet. Nutraceuticals have not been established as a treatment option for these conditions.
Peptides: Aldh7a1-related disorder, also known as pyridoxine-dependent epilepsy (PDE), is a genetic condition caused by mutations in the ALDH7A1 gene. This gene is responsible for producing an enzyme involved in lysine metabolism. The deficiency of this enzyme leads to the accumulation of toxic substances that can cause seizures. Treatment typically includes supplementation with pyridoxine (vitamin B6) and a lysine-restricted diet.

Peptide therapy or nanotechnology-based treatments are not standard approaches for managing this disorder. The primary focus remains on dietary management and vitamin B6 supplementation to control seizures and other symptoms associated with the condition. Experimental treatments involving peptides or nanotechnology are not currently established for ALDH7A1-related disorder.